biotech news today obesity drugs glp-1 Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine What is the pipeline for
Description
The first cohort comprised individuals who started and continued either a GLP-1 receptor agonist or DPP-4 inhibitor for the first time between January 1, 2007, and December 31, 2020
Wang Z, Sun J, Han R, et al
Focus on key areas: your waist (half an inch above your belly button), hips at their widest point, thighs, and upper arms
Conversely, data from clinical trials have showed an increased risk of incident heart failure with DPP4 inhibitors compared to placebo
It is now recognized as the most common cause of chronic liver disease, with an estimated prevalence of 32.4% in the general population
doi: 10.1016/j.bbrc.2019.06.112 63 SchrijversEMCWittemanJCMSijbrandsEJGHofmanAKoudstaalPJBretelerMMB
